<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01606969</url>
  </required_header>
  <id_info>
    <org_study_id>4-2012-0062</org_study_id>
    <nct_id>NCT01606969</nct_id>
  </id_info>
  <brief_title>Comparison of Epinephrine-lidocaine Solution and Dexmedetomidine -Lidocaine Solution</brief_title>
  <official_title>Randomized Controlled Trial to Comparison of Epinephrine-lidocaine Solution and Dexmedetomidine -Lidocaine Solution for the Effect on Hemodynamic Response Due to Scalp Infiltration in Patients Undergoing Craniotomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Scalp infiltration with Epinephrine- containing lidocaine solution is common method for
      craniotomy but it may result in transient but significant hypotension in patients undergoing
      neurosurgery. Dexmedetomidine, a potent alpha2 adrenoceptor agonist which dose-dependently
      reduces arterial blood pressure and heart rate, decreases the hemodynamic and catecholamine
      response, and dexmedetomidine has an effect of peripheral vasoconstriction thus it is thus
      theologically appropriate for reducing bleeding during scalp incision in craniotomy.

      The aim of this study is to compare the effect of dexmedetomidine-lidocaine solution on
      hemodynamic response, scalp bleeding to epinephrine-lidocaine solution.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean arterial pressure</measure>
    <time_frame>before and after scalp injection</time_frame>
    <description>before scalp injection(T0), after scalp injection every half minute until five minutes(T0.5, T1, T1.5, T2, T2.5, T3, T3.5, T4, T4.5, T5), every minute(T6, T7, T8, T9, T10, T11, T12, T13, T14, T15)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Craniotomy</condition>
  <arm_group>
    <arm_group_label>Dex group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dexmedetomidine-lidocaine solution,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>epinephrine-lidocaine solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>scalp infiltration solution</intervention_name>
    <description>Dex group: Dexmedetomidine 2mcg/ml-containing 1% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)</description>
    <arm_group_label>Dex group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>scalp infiltration solution</intervention_name>
    <description>1:100000 epinephrine-containing 1% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I-II

          -  Aged between 20 and 70 year

          -  general anesthesia for craniotomy

        Exclusion Criteria:

          -  Congestive heart failure, coronary artery occlusive disease

          -  Bradycardia &lt; 50 BPM, 2nd degree &lt; AV block

          -  Poorly controlled hypertension

          -  ÃŸ blocker medication

          -  Coagulopathy

          -  Pregnancy, nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Severance hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2012</study_first_submitted>
  <study_first_submitted_qc>May 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2012</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>epinephrine</keyword>
  <keyword>lidocaine</keyword>
  <keyword>scalp infiltration</keyword>
  <keyword>craniotomy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

